Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX24.571,22+1,37 %

Gold3.297,59-0,09 %

Öl (Brent)69,69-0,63 %

Dow Jones44.464,83+0,51 %

US Tech 10022.842,09+0,62 %

EUR/USD1,17165-0,07 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Nanobiotix Aktie

Aktie

ISIN: FR0011341205 WKN: A1J7EB SYM: 5NR Land Flagge FR

Frankreich

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

4,6550

EUR

-1,17 %

-0,0550 EUR

Letzter Kurs 15:33:42 Tradegate

Nanobiotix Aktie kaufen

Geldkurs

15:34:46

4,6350

EUR

700 STK

Briefkurs

15:34:46

4,6550

EUR

700 STK

BEI SMARTBROKER+ HANDELN

Hinweis
Verlängerte Handelszeiten
Ab sofort von 07:30 bis 23:00 Uhr

Baader Tragding

Neueste Nachrichten

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) 07.07.25 · globenewswire · Nanobiotix
Voting Rights and Shares Capital of the Company 10.06.25 · globenewswire · Nanobiotix
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference 28.05.25 · globenewswire · Nanobiotix
Nanobiotix Provides First Quarter 2025 Operational and Financial Update 21.05.25 · globenewswire · Nanobiotix
Voting Rights and Shares Capital of the Company 14.05.25 · globenewswire · Nanobiotix
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ 12.05.25 · globenewswire · Nanobiotix
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer 05.05.25 · globenewswire · Nanobiotix
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call 30.04.25 · globenewswire · Nanobiotix
Voting Rights and Shares Capital of the Company 14.04.25 · globenewswire · Nanobiotix
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results 02.04.25 · globenewswire · Nanobiotix
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 31.03.25 · globenewswire · Nanobiotix
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC 27.03.25 · globenewswire · Nanobiotix

1
2
…
3

Meistgelesen

7 Tage
30 Tage
12 Monate

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for ... 120 Leser

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for ... 120 Leser
Voting Rights and Shares Capital of the Company 108 Leser

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results 336 Leser
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for ... 276 Leser
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference 212 Leser
Voting Rights and Shares Capital of the Company 176 Leser
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 ... 160 Leser
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms 152 Leser
Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025 144 Leser
Nanobiotix Provides First Quarter 2025 Operational and Financial Update 140 Leser
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next ... 140 Leser
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in ... 128 Leser